Article - 18/03/2019 EHR and PHR: digital records in the German healthcare system EHRs, i.e. electronic health records (German: Patientenakte, ePA), are hailed as the key to increasing the quality of care. The Appointment Service and Supply Act (TSVG), adopted on 14th March 2019, requires the German statutory health insurance funds to provide policyholders with electronic health records from 1st January 2021 onwards.https://www.gesundheitsindustrie-bw.de/en/article/news/ehr-and-phr-digital-records-in-the-german-healthcare-system
Article - 05/03/2019 Vaccination against oncogenic Epstein-Barr viruses Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.https://www.gesundheitsindustrie-bw.de/en/article/news/vaccination-against-oncogenic-epstein-barr-viruses
Article - 21/02/2019 Using neuromedical artificial intelligence responsibly Brain-computer interfaces are the latest developments in the neurotechnology field. They are used to record brain activity, which is then decoded with artificial intelligence techniques and converted into control signals for robots or computers. While this brings hope to severely paralysed people, it also implies risks due to the interest of companies like Google and Facebook in this type of data.https://www.gesundheitsindustrie-bw.de/en/article/news/using-neuromedical-artificial-intelligence-responsibly
Article - 07/02/2019 Artificial intelligence in ophthalmology Retinal diseases such as age-related macular degeneration (AMD) are now treatable. However, it is hard to predict individual disease progression. A group of researchers at the University Eye Centre in Freiburg are currently developing a new system which is hoped will allay fears and improve therapy planning. The system uses artificial intelligence to predict therapeutic outcome from image and patient data. Initial results are already available.https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-intelligence-in-ophthalmology
Article - 30/01/2019 candidum – computer-assisted enzyme design Industry has been using enzymes for over a hundred years. While it initially had to content itself with natural enzymes, it is now increasingly possible to design tailor-made biocatalysts with specific properties. The start-up company candidum GmbH from Stuttgart promises to achieve this faster than ever before - mostly thanks to accelerated virtual screening.https://www.gesundheitsindustrie-bw.de/en/article/news/candidum-computer-assisted-enzyme-design
Article - 29/01/2019 Targeted RNA editing with the body’s own enzyme activity Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-rna-editing-with-the-bodys-own-enzyme-activity
Article - 24/01/2019 Scientists to combat antibiotic-resistant bacteria in wastewater In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.https://www.gesundheitsindustrie-bw.de/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
Expert interview - 16/01/2019 Cybersecurity is an important issue for the pharmaceutical industry In an increasingly interconnected world, the pharmaceutical and biotechnology sectors need to be aware of cybersecurity threats in manufacturing. We talked about these threats with Holger Mettler who is in charge of computer system validation and cybersecurity at Exyte (formerly M + W), a global enterprise that designs, engineers and constructs complex manufacturing facilities and buildings for the life sciences industry.https://www.gesundheitsindustrie-bw.de/en/article/news/cybersecurity-is-an-important-issue-for-the-pharmaceutical-industry
Article - 10/01/2019 Stocktaking and recommendations for action: the BBAW’s fourth gene technology report In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…https://www.gesundheitsindustrie-bw.de/en/article/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
Company profile - 09/01/2019 HQS Quantum Simulations for industrial quantum mechanics applications The door to the quantum world is opening wider and wider. Behind it is a whole new view of materials and molecules. Quantum mechanics applications not only benefit science, they also offer huge economic potential. The Karlsruhe start-up HQS Quantum Simulations is playing a pioneering role in quantum simulations for the chemical and pharmaceutical industries.https://www.gesundheitsindustrie-bw.de/en/article/news/hqs-quantum-simulations-for-industrial-quantum-mechanics-applications
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Funding Future Insight Prize Funding programme, Funded by: Merck KGaA, sb_search.searchresult.label.programSubmissionDate: 31/12/2022 https://www.gesundheitsindustrie-bw.de/en/database/funding/future-insight-prize
The Baden-Württemberg healthcare industry Location BW https://www.gesundheitsindustrie-bw.de/en/location/location-bw
Dossier - 06/03/2018 Big data - the big promise of the new digitised world Big data is a widely used buzzword in today's information era. The use of big data in the digital world presents both an opportunity and a risk. Mass data is now used and analysed in almost all areas of life. Even the healthcare sector is undergoing extensive digitisation.https://www.gesundheitsindustrie-bw.de/en/article/dossier/big-data-the-big-promise-of-the-new-digitised-world
Dossier - 17/01/2017 Phytopharmaceuticals – fighting disease with natural substances Phytopharmaceuticals are herbal medicines whose efficacy is down to one or several plant substances or active ingredients. They have been used for treating diseases since time immemorial. This traditional knowledge is still the basis for many medicinal products made from plants or parts thereof. Herbal medicines have been produced in Baden-Württemberg for many generations.https://www.gesundheitsindustrie-bw.de/en/article/dossier/phytopharmaceuticals-fighting-disease-with-natural-substances
Overview The event has already taken place https://www.gesundheitsindustrie-bw.de/en/event/the-event-has-already-taken-place
Overview Details https://www.gesundheitsindustrie-bw.de/en/database/healthcare-industry-database/details
High-tech - 20/10/2016 Industry 4.0 in the medical technology and pharmaceutical industry sectors The digitalisation of industry affects the entire value chain. From individual products to digitising workflows in companies and connecting companies with clients and service providers via the Internet of Things – Industry 4.0 makes completely new manufacturing processes possible and requires new and specific business models.https://www.gesundheitsindustrie-bw.de/en/article/dossier/industry-40-in-the-medical-technology-and-pharmaceutical-industry-sectors
Dossier - 14/06/2016 CRISPR/Cas – genome editing is becoming increasingly popular The number of publications and patents that involve the CRISPR/Cas system has been increasing exponentially since the technique was first described a few years ago. The increase in funding for projects involving CRISPR/Cas also demonstrates how powerful this new method is. The targeted modification of genomes (also called gene or genome editing) using CRISPR/Cas is extraordinarily accurate and also has the potential to cure hereditary diseases. https://www.gesundheitsindustrie-bw.de/en/article/dossier/crisprcas-genome-editing-is-becoming-increasingly-popular
Dossier - 18/04/2016 Epigenetics – heritable traits without changing the DNA sequence Epigenetics, i.e. the inheritance of traits that does not involve a change in the DNA sequence, was once a controversial subject that has since become a central focus of biological research. Epigenetic inheritance is now studied by numerous national and international research programmes. Many cellular regulatory and differentiation processes are controlled by epigenetic mechanisms that take place on different levels.https://www.gesundheitsindustrie-bw.de/en/article/dossier/epigenetics-heritable-traits-without-changing-the-dna-sequence